All In Biotech

Drug Trial Radar · NCT03761017

MGD019 DART® Protein in Unresectable/Metastatic Cancer

A Phase 1, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in Patients With Unresectable or Metastatic Neoplasms

Last checked: Nov 19, 2026Latest source record: Mar 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

162

Actual

Start

Dec 12, 2018

Primary completion

Aug 29, 2024

Study completion Jan 27, 2025

Sponsor

Lead sponsor
MacroGenicsIndustry
Sponsor type
Industry
First posted
Dec 3, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of lorigerlimab. This Phase 1, open-label study will characterize safety, dose-limiting toxicities (DLTs), and maximum tolerated/administered dose (MTD/MAD) of MGD019. Dose escalation will occur in a 3+3+3 design in patients with advanced solid tumors of any histology. Once the MTD/MAD is determined, a Cohort Expansion Phase will be enrolled to further characterize safety and initial anti-tumor activity in patients with specific tumor types anticipated to be sensitive to dual checkpoint blockade.

Conditions

  • Squamous Cell Non Small Cell Lung Cancer
  • Prostate Cancer Metastatic
  • Cutaneous Melanoma
  • Colorectal Cancer
  • Advanced Cancer
  • Solid Tumor, Adult

Interventions

  • LorigerlimabBiological

    Bispecific DART protein binding PD-1 and CTLA-4

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse eventsTime frame: 30 days after last dose

Locations

39 sites in 5 countries. Site status is shown where the registry gives one.

  • University of Chicago Medical Center

    Chicago, Illinois

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • START Midwest

    Grand Rapids, Michigan

  • Oncology Hematology West p.c. dba Nebraska Cancer Specialists

    Grand Island, Nebraska

  • Nebraska Cancer Specialists

    Omaha, Nebraska

  • Providence Portland Medical Center

    Portland, Oregon

  • UPMC Hillman Cancer Center

    Camp Hill, Pennsylvania

  • UPMC Hillman Cancer Center

    Carlisle, Pennsylvania

  • UPMC Hillman Cancer Center

    Erie, Pennsylvania

  • UPMC Pinnacle Harrisburg

    Harrisburg, Pennsylvania

  • UPMC Pinnacle - Community Osteopathic Medical Sciences Pavilion (MSP)

    Harrisburg, Pennsylvania

  • UPMC Pinnacle - Ortenzio Cancer Center (OCC)

    Mechanicsburg, Pennsylvania

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • UPMC Hillman Cancer Center at UPMC Memorial

    York, Pennsylvania

  • The Sarah Cannon Research Institute / Tennessee Oncology

    Nashville, Tennessee

  • Complex Oncology Center - Burgas" EOOD, Department of Medical Oncology

    Burgas, Bulgaria

  • Multiprofile Hospital for Active Treatment-Uni Hospital

    Panagyurishte, Bulgaria

  • Multiprofile Hospital for Active Treatment "Heart and Brain"" EAD, Clinic of Medical Oncology

    Pleven, Bulgaria

  • Complex Oncology Center - Ruse EOOD

    Rousse, Bulgaria

  • University Mulitprofile Hospital for Active Treatment "Sv. Ivan Rilski

    Sofia, Bulgaria

  • University Clinical Centre, Early Clinical Trials Unit

    Gdansk, Poland

  • Pratia MCM Krakow

    Krakow, Poland

  • Europejskie Centrum Zdrowia Otwock

    Otwock, Poland

  • Med-Polonia Sp. z.o.o.

    Poznan, Poland

  • LUX MED Onkologia Sp. z.o.o.

    Warsaw, Poland

  • Narodowy Instytut Onkologii im

    Warsaw, Poland

  • Mazovian Onkological Hospital

    Wieliszew, Poland

  • Hospital Ruber Internacional

    Madrid, Spain

  • Hospital Universitario La Princesa

    Madrid, Spain

  • ICO Badalona / Hospital Universitari Germans Trias i Pujol

    Badalona, Barcelona, Spain

  • Communal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro

    Dnipro, Ukraine

  • Communal Non-Profit Enterprise "Regional Center of Oncology", Oncosurgical Department of Head and Neck

    Kharkiv, Ukraine

  • Communal Nonprofit Enterprise "Regional Clinical Oncology Center of Kirovohrad Regional Council"

    Kirovohrad, Ukraine

  • Kyiv City Clinical Oncological Centre

    Kyiv, Ukraine

  • National Cancer Institute of Ukraine

    Kyiv, Ukraine

  • Sumy Clinical Oncological Hospital

    Sumy, Ukraine

  • Communal Nonprofit Enterprise "Podilsky Regional Center of Oncology"

    Vinnytsia, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.